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Abstract
Interleukin 2 (IL-2) and Interleukin 15 (IL-15) are common γ-chain family cytokines involved in
regulation of T cell differentiation and homeostasis. Despite signaling through the same receptors,
IL-2 and IL-15 have non-redundant roles in T cell biology, both physiologically and at the cellular
level. The mechanisms by which IL-2 and IL-15 trigger distinct phenotypes in T cells remain
elusive. To elucidate these mechanisms, we performed a quantitative comparison of the
phosphotyrosine signaling network and resulting phenotypes triggered by IL-2 and IL-15. This
study revealed that the signaling networks activated by IL-2 or IL-15 are highly similar and that T
cell proliferation and metabolism are controlled in a quantitatively distinct manner through
IL-2/15 receptor signal strength independent of the cytokine identity. Distinct phenotypes
associated with IL-2 or IL-15 stimulation therefore arise through differential regulation of
IL-2/15R signal strength and duration due to differences in cytokine-receptor binding affinity,
receptor expression levels, physiological cytokine levels, and cytokine-receptor intracellular
trafficking kinetics. These results provide important insights into the function of other shared
cytokine and growth factor receptors, quantitative regulation of cell proliferation and metabolism
through signal transduction, and improved design of cytokine based clinical immunomodulatory
therapies for cancer and infectious diseases.
Introduction
Interleukin-2 (IL-2) and Interleukin-15 (IL-15) are critically involved in the regulation of
peripheral T lymphocyte homeostasis and differentiation. IL-2 and IL-15 were among the
first cytokines shown to trigger proliferation of activated T cells in vitro and in vivo.1,2 Their
ability to expand T cell numbers upon exogenous stimulation has made both cytokines
extremely important in clinical settings as immunomodulatory and cancer
immunotherapeutic agents.3–5 Both cytokines mediate their effects on T cells through a
heterotrimeric receptor complex consisting of a cytokine specific α-chain (IL-2Rα or
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IL-15Rα), the common γ-chain (γc), and the IL-2/15 receptor β-chain (β).6–9 The α-chains
function primarily as high affinity ligand capture receptors while signal transduction occurs
exclusively through the β and γc chains, which are constitutively associated with the Janus
kinases (JAK).10 As a consequence of sharing the β and the γc chains, stimulation of T cells
with IL-2 and IL-15 results in the activation of similar signaling pathways which include the
JAK-STAT, the Ras-Raf-MAPK, and the PI3K-Akt pathways.4,10,11 Additionally,
stimulation of T cells with IL-2 or IL-15 has been shown to result in the induction of similar
gene expression profiles.8,12,13 Despite signaling through the same receptors and sharing
common effector pathways, multiple studies have reported unique and even antagonistic
roles for IL-2 and IL-15 in the T cell immune response. IL-2 is critical for the clonal
expansion of activated T cells, differentiation of effector and memory cytotoxic T
lymphocytes (CTLs), and regulation of T cell peripheral tolerance.4,14,15 In contrast; IL-15
is critically involved in the maintenance and survival of memory CD8+ T cells, naïve CD8+
T cells, and natural killer cells. IL-2 and IL-15 stimulation of T cells can result in distinct
phenotypic responses even at the cellular level.4,16,17 Antigen activated mouse CD8+ T cells
cultured with IL-2 are metabolically more active and larger in size than cells cultured with
IL-15 despite proliferating equivalently.18 Additionally, a transient pulse of IL-15, but not
IL-2, triggers T cell proliferation in an in vitro assay.19,20
Multiple factors may contribute to functional differences triggered by IL-2 and IL-15
stimulation of T cells. IL-2 and IL-15 differ in their mode of presentation to T cells. IL-2
directly binds IL-2Rα chains expressed on T cells, whereas IL-15/IL-15Rα complexes on
non-T cells are presented in trans to IL-2/15βγc complexes expressed on T cells in addition
to directly binding IL-15Rα chains expressed on T cells.4,19,21 Binding affinity of cytokines
for their respective α-chains may also play an important role in differentiating the response
to IL-2 and IL-15, as the binding affinity of IL-15 for IL-15Rα chain is approximately 1000-
fold higher compared to the affinity of IL-2 for IL-2Rα.19,20 In support of this, IL-2 mutants
engineered with significantly higher binding affinity for IL-2Rα trigger equivalent
proliferation compared to IL-15 upon pulse stimulation of T cells.20 Signaling kinetics have
also been implicated in differential regulation of T cell phenotype, as differences in cell size
and metabolic activity between antigen-activated mouse CD8+ T cells cultured with IL-2
and IL-15 were associated with different kinetics of PI3K/PDK1 signaling triggered by the
two cytokines.18 Although these studies have unveiled myriad possibilities for the distinct
phenotypes resulting from stimulation with these two cytokines, the molecular mechanisms
leading to differential regulation of T cell proliferation and metabolism through IL-2 and
IL-15 remain incompletely characterized.
To elucidate the molecular mechanisms underlying the distinct T cell phenotypes driven by
IL-2 and IL-15, we compared phosphotyrosine signaling networks triggered by the two
cytokines and determined that the signaling networks activated by IL-2 and IL-15 are
virtually identical. Since the disparate phenotypic response was not encoded in the signaling
network, we focused on the role of IL-2/15R signal strength and duration in regulating cell
proliferation and metabolic activity in engineered and primary human T cells. Our results
indicate that the strength of signal is directly proportional to cellular metabolic activity and
increase in cell size, while cell proliferation requires a constant signal above a threshold.
Intriguingly, phenotypic regulation is independent of cytokine identity when presentation
and duration are held constant. These results provide key insights into the differential
regulation of cell proliferation and metabolic activity through shared signaling receptors
which ultimately informs improved cytokine based immunotherapies for the treatment of
cancer, autoimmune disorders, and infectious disease.
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Materials and Methods
Antibodies and Reagents
Recombinant human IL-2 and IL-15 were purchased from Peprotech (Rocky Hill, NJ). High
affinity mutant IL-2 (mtIL-2) was a kind gift from K.D. Wittrup (MIT Koch Institute,
Cambridge, MA). JAK Inhibitor I (JI) was purchased from EMD Millipore (Billerica, MA).
Carboxyfluorescein succinimidyl ester (CFSE) and CellTrace Violet were purchased from
Life Technologies (Grand Island, NY). Phycoerythrin conjugated anti-IL-2, anti-IL-15, and
anti-IL-2Rβ, and Allophycocyanin conjugated anti-IL-2Rα and anti-IL-15Rα mAbs were
purchased from R&D Systems (Minneapolis, MN). Alexa-fluor 647 conjugated anti-
pSTAT5 (pY694) and anti-pS6 (pS235/pS236) antibodies were purchased from BD
Biosciences (San Jose, CA). Human anti-CD3ε (clone UCHT1) and human anti-CD28
(clone 37407) mAbs were purchased from R&D Systems (Minneapolis, MN).
Cell Culture
F15R-Kit cell culture—F15R-Kit cells were a kind gift from the K.D. Wittrup (MIT,
Cambridge, MA). F15R-Kit cells were maintained at 37 °C and 5% CO2 in RPMI 1640
supplemented with 10% FBS (heat inactivated), 2mM L-Glutamine, 1mM sodium pyruvate,
100U/ml penicillin-streptomycin, and 900μg/ml G418. Unless otherwise indicated, cells
were cultured in 80pM IL-2 at a density of 2–3×105 cells/ml and passaged every 48h.
Primary human T cell isolation and culture—Peripheral blood mononuclear cells
(PBMCs) were isolated using ficoll-paque gradient centrifugation of unpurified human
buffycoats (Research Blood Components, Boston, MA). CD4+ and CD8+ T cells were
isolated from PBMCs using magnetic separation with EasySep CD4+ and CD8+ negative
enrichment kits (STEMCELL Technologies) and maintained in RPMI 1640 supplemented
with 10% FBS (heat inactivated), 100U/ml penicillin-streptomycin, 2mM L-Glutamine, and
1mM sodium pyruvate.
Mass spectrometry based phosphotyrosine profiling analysis
Lysate preparation for mass spectrometry based phosphotyrosine analysis—
2 × 107 cytokine starved F15R-Kit cells were suspended in fresh culture medium at a
density of 4 × 105 cell/ml and stimulated with 500pM IL-2 or 500pM IL-15 for 15min. Cells
were washed twice with 50 ml phosphate buffered saline (PBS) and lysed in 8M urea
supplemented with 1mM sodium orthovanadate. Cells cultured in medium alone were used
as unstimulated controls. The lysates were incubated on ice for 20min then stored in −80°C.
Reduction, Alkylation and Tryptic Digestion—Proteins from cell lysates were
quantified using the bicinchoninic assay (Pierce, Thermo Scientific, Rockford, IL), reduced
using 10mM DL-Dithiothreitol (DTT) at 56°C for 45min, and alkylated using 50mM
iodoacetamide at room temperature in the dark for 1 hour. Excess iodoacetamide was
quenched with DTT to a final concentration of 25mM. Proteins were subsequently digested
with trypsin (sequencing grade, Promega, Madison, WI), at an enzyme/substrate ratio of
1:100, at room temperature overnight in 100mM ammonium acetate (pH 8.9). Trypsin
activity was quenched through addition of formic acid to a final concentration of 5%.
Samples were desalted using a C18 cartridge (Waters, Milford, MA) and peptides were
lyophilized and stored at −80°C.
iTRAQ labeling—Peptide labeling with iTRAQ 8plex (AB Sciex, Framingham, MA) was
performed as previously described. Briefly, for each analysis, approximately 400μg (prior to
desalting and processing) peptide for each condition was labeled with iTRAQ 8plex reagent.
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Lyophilized samples were dissolved in 30μl of 500mM triethylammonium bicarbonate, pH
8.5, and the iTRAQ reagent was dissolved in 70μl of isopropanol. The solution containing
peptides and iTRAQ reagent was vortexed, incubated at room temperature for 2 hours and
concentrated to 40μl. Samples labeled with eight different isotopic iTRAQ reagents were
combined and concentrated. Peptides were then dissolved in 400μl of IP buffer (100mM
Tris, 100mM NaCl, and 1% Nonidet P-40, pH 7.4) and the pH was adjusted to 7.4 prior to
phosphotyrosine immunoprecipitation (IP). 3 biological replicates of F15R-Kit cells
stimulated with 500pM IL-2 or IL-15 for 15 minutes, and two biological replicates of
unstimulated cells (total 8 conditions) were labeled, combined and analyzed together.
Phosphotyrosine Enrichment—Protein G agarose (80μl, EMD Millipore, Billerica,
MA) beads were incubated with 3 phosphotyrosine antibodies; 12μg PT66 (Sigma-aldrich,
St. Louis, MO), 12μg pY100 (CST, Beverly, MA) and 12μg 4G10 (EMD Millipore,
Billerica, MA) and 200μlof IP buffer (100mM Tris, 1% NP-40, pH 7.4) was added and the
mixture incubated for 8 hours at 4°C with rotation. iTRAQ 8plex labeled peptides re-
suspended in IP buffer were added to antibody-conjugated protein G agarose beads and
incubated overnight at 4°C with rotation. Peptide conjugated protein G agarose beads were
rinsed with 400μl of IP buffer and 4 × 400μl of rinse buffer (100mM Tris, pH 7.4), and
peptides were eluted into 70μl of 100mM glycine (pH 2.0). Phosphotyrosine peptides were
further enriched using an offline immobilized metal affinity chromatography (IMAC)
column. Peptides retained on the IMAC column were loaded onto a C18 pre-column and
were subsequently separated by reverse phase HPLC (Agilent) over a 150 minute gradient
prior to nanoelectrospray into an Orbitrap Elite mass spectrometer (Thermo scientific) for
phosphotyrosine analyses. To correct for slight variations in the amount of sample in each of
the iTRAQ channels, the mean iTRAQ ratios for all proteins identified in each biological
replicate analysis was used to normalize the data. The mass spectrometer was operated in
data-dependent mode with a full scan MS spectrum followed by MS/MS (CID was set at
35% energy for sequence information and HCD at 75% energy for iTRAQ quantification for
Orbitrap Elite) for the top 10 precursor ions in each cycle. Ion trap injection time was set to
100 ms and FTMS injection time was set to 1000 ms with a resolution of 60000 across m/z
400–2000. For IT and FT-MS/MS scans, fragmentation was carried out on ions above a
threshold of 500 counts and an FTMS resolution of 7500.
Phosphotyrosine Data analysis—Raw mass spectral data files (.RAW files) were
converted into .mgf file format using DTAsupercharge 1.31 (http://
msquant.sourceforge.net/). All resulting MS/MS peak lists were searched against a NCBI
UniProt 2009 database containing Homo sapiens protein sequences (37, 743 entries) using
Mascot version: 2.1.03 (Matrix Science). Trypsin enzyme specificity was applied with a
maximum of 1 missed cleavage. Mass tolerance for precursor ions was set to 10 ppm and
fragment ion mass tolerance was 0.8 Da. MS/MS spectra searches incorporated fixed
modifications of carbamidomethylation of cysteine and iTRAQ 8plex modification of
lysines and peptide N-termini. Variable modifications were oxidized methionine, and
phosphorylation of serine, threonine, and tyrosine residues. Phosphotyrosine peptides were
initially filtered using an arbitrary mascot score cut-off of 25. Precursor ions were manually
evaluated and peptides with contaminating peaks present within the isolation window (ions
with intensity > 25% of the base peak ± 1.5 m/z around the selected precursor ion m/z) were
discarded as they may contribute to the relative iTRAQ intensities. iTRAQ intensity values
were extracted from HCD scans using an in house python script which converted iTRAQ
intensities into .txt format. We further imported this into Excel, and iTRAQ values were
isotope corrected based on the iTRAQ8plex correction matrix (AB Sciex). Phosphotyrosine
peptide iTRAQ ratios were normalized based on the mean relative protein quantification
ratios obtained from the total protein.
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Western Blotting
F15R-Kit cells were lysed on ice with radio immunoprecipitation assay (RIPA) buffer
(50mM Tris-HCl, 150mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, and 0.1% sodium
dodecyl sulfate (SDS)) supplemented with phosphatase and protease inhibitor (Thermo-
Fisher Scientific, Rockford, IL). The lysates were cleared through centrifugation at
10,000Xg for 10min at 4°C, and boiled with laemmli sample buffer at 95°C for 5min.
Sample protein concentrations were determined using the bicinchoninic acid (BCA) protein
assay (Thermo-Fisher Scientific, Rockford, IL). The samples were separated via
polyacrylamide gel electrophoresis using 10% polyacrylamide gels and transferred onto
polyvinylidene fluoride (PVDF) membranes. The membranes were probed overnight at 4°C
with primary antibody, then washed and stained with HRP-conjugated goat anti-mouse or
goat anti-rabbit secondary antibodies. The blots were developed using SuperSignal West
Pico Chemiluminescent Substrate kit (Thermo-Fisher Scientific, Rockford, IL). RIPA buffer
and laemmli sample buffers were purchased from Boston BioProducts (Ashland, MA). Pre-
cast 10% Tris-HCl polyacrylamide gels were purchased from BioRad (Hercules, CA). Anti-
pSTAT5 (pY694), anti-STAT5, anti-pERK, anti-ERK, and anti-β-actin antibodies were
purchased from Cell Signaling Technology (Beverly, MA).
Flow Cytometry Analysis
Cell surface staining was performed according to the manufacturer’s recommended protocol
for the particular antibody used. Phycoerythrin conjugated antibodies against human IL-2R
α, IL-15Rα, IL-2Rβ, and IL-2Rγ proteins were purchased from R&D systems (Minneapolis,
MN). Alexa-647 conjugated antibody against human 40S ribosomal protein S6
phosphorylated at Ser235 and Ser236 were purchased from BD Biosciences (San Jose, CA).
For intracellular staining, cells were washed and fixed in a 1:1 dilution of PBS and BD
Cytofix Buffer for 15min at room temperature. Fixed cells were permeabilized on ice for
30min in BD Phosflow Perm Buffer III and washed and stained with fluorochrome
conjugated antibody (5 × 105 cells in 50μl) at 4°C for 60min. Samples were analyzed using
either BD Accuri C6 cytometer or BD LSRFortessa cell analyzer (BD Biosciences) and data
were analyzed using the FlowJo software (TreeStar Inc., Ashland, OR). Flow cytometry
events were acquired ungated and live lymphocyte gates were created based on their forward
and side light scatter profiles using FlowJo.
Proliferation assays
Cell counting using Trypan Blue exclusion—F15R-Kit cells cytokine starved for 48h
were resuspended in fresh media at a density of 2 × 105 cells/ml and then cultured in the
presence or absence of cytokines. For the pulse bioassay, cytokine starved F15R-Kit cells
were stimulated with cytokine for 30min, washed three times and resuspended in cytokine-
free culture media, and maintained at 37 °C and 5% CO2. Viable cell numbers were
determined through Trypan blue exclusion using the Vi-CELL Cell Viability Analyzer
(Beckman Coulter).
CFSE and CellTrace Violet staining—Cells were labeled with CFSE or CellTrace
Violet dyes according to the manufacturer’s protocols at a final concentration of 0.5–2.5μM
and 5μM, respectively. CFSE and CellTrace Violet fluorescence levels were measured using
the BD Accuri C6 cytometer and the BD LSRFortessa analyzer respectively.
Cell size and proliferation experiments
F15R-Kit Cells—CFSE labeled cytokine-starved F15-Kit cells were seeded at a density of
2 × 105 cells/ml and pretreated with the indicated doses of JAK inhibitor (JI) for 30min at 37
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°C. The cells were then cultured with 500pM of IL-2 or IL-15 at 37 °C and 5% CO2 for 6
days.
Primary human CD4+ and CD8+ T cells—Purified CD4+ and CD8+ human primary T
cells were labeled with CFSE (2.5μM) and added to 12-well tissue culture plates coated with
10μg/ml anti-CD3 mAb, supplemented with soluble anti-CD28 mAb (0.5μg/ml), and
cultured at 37 °C and 5% CO2 for 72h. Cells cultured on uncoated plates in the absence of
anti-CD28 served as unstimulated controls. Activated cells were washed, suspended in fresh
medium, and cultured with the indicated dose of JI and 1nM IL-2, 1nM IL-15, or medium
alone for 4 days.
Cells were passaged and cytokine and inhibitor levels were replenished every 48h. Forward
scatter, CFSE dilution, and pSTAT5 levels were measured using the BD Accuri C6
cytometer at the indicated time-points after cytokine addition.
Glucose and Lactate measurements
F15R-Kit cells were cultured for 6 days with the indicated dose of JI and 500pM of IL-2 or
IL-15. On day 6, cells were washed and seeded at a density of 2 × 105 cells/ml in fresh
media, inhibitor, and cytokine. Culture media were collected 48h later and glucose and
lactate levels were measured using the YSI 7100 Select Biochemistry Analyzer (YSI
Incorporated, Yellow Springs, OH).
Statistical Analysis
Mean iTRAQ fold changes of individual phosphotyrosine sites generated through LC-MS/
MS analysis were compared using unpaired student’s t-test. A p-value of less than 0.05 was
considered statistically significant. For multiple comparison testing, one-way analysis of
variance (ANOVA) was performed followed by unpaired student’s t-tests for comparison of
individual populations. To account for the presence of type I error due to multiple
hypotheses testing, p-values used for the determination of statistical significance were
adjusted using the false discovery rate control method to correspond to a particular family-
wise error rate (αfw). P-values less than the adjusted p-values corresponding to αfw of 0.05
were considered significant.
Results
Phosphotyrosine profiling of IL-2 or IL-15 stimulated T cells reveals the activation of highly
similar signaling networks
To quantitatively compare IL-2 and IL-15 mediated signal transduction in T cells at a
network level, differentially iTRAQ8plex labeled tyrosine phosphorylated peptides from
F15R-Kit cells stimulated for 15min with either no cytokine, IL-2 or IL-15 were
immunoprecipitated with pan-specific anti-phosphotyrosine antibodies and analyzed using
reverse phase LC-MS/MS (figure 1A).22–25 The choice of F15R-Kit cells, a human
leukemia derived T cell line, as a model system was based on constitutive and stable
expression of all four receptors of the IL-2/15R system in these cells (supplementary figure
S1A–B).26 Phosphotyrosine profiling analysis led to the identification and quantification of
85 unique phosphorylation sites (76 pTyr, and 9 pSer/Thr) on 81 proteins measured across
three biological replicates (figure 1B). To determine the minimum magnitude of difference
detected through LC-MS/MS analysis in the present study, we analyzed the relative standard
deviation (through calculation of the average coefficient of variation) across all conditions
and biological replicates. Using twice the relative standard deviation as a cutoff, we defined
a 1.54 fold-change in iTRAQ values as the minimum difference reliably detected through
MS analysis in the current study. It is important to note that the relative standard deviation
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for the LC-MS/MS analysis is a combination of both the technical variations of LC-MS/MS
and cell culture techniques and the inherent biological noise of our cell culture system.
Consequently, the minimum difference threshold of 1.54 fold is specific to the present
analysis and does not represent the sensitivity of the LC-MS/MS technique by itself. Out of
85 total phosphorylation sites, 41 sites (38 pTyr and 3 pSer/Thr) from 39 proteins showed a
1.54 fold or higher increase in phosphorylation level upon IL-2 or IL-15 stimulation. The
IL-2 and IL-15 responsive phosphorylation sites belonged to proteins involved in the
regulation of multiple cellular processes including cytoskeletal regulation, endocytosis, and
protein translation, in addition to proteins known to be involved in signal transduction
(figure 1C, supplementary table S1). Only 2 of the 39 IL-2 and IL-15 responsive proteins
showed quantitatively distinct tyrosine phosphorylation responses, i.e. greater than 1.54 fold
change, between IL-2 and IL-15 stimulation. IL-2 stimulation resulted in approximately 2.7-
fold increase in phosphorylation of signal transducing adaptor molecule 2 (STAM2) on
Tyr374 and a 2.0-fold increase in phosphorylation of vacuolar protein sorting 18 (VPS18) on
Tyr32 relative to IL-15 stimulation (figure 2A). Both of these proteins have been shown to
be involved in protein trafficking, endosomal sorting, and endocytosis (supplementary table
S1).27–30
Overall IL-2 or IL-15 stimulation resulted in an equivalent increase in phosphorylation
levels of canonical IL-2/15R signaling pathway proteins, confirming previous reports (figure
1D, figure 2B). Beyond canonical signaling pathways, our analysis demonstrated that
stimulation with IL-2 or IL-15 resulted in equivalent tyrosine phosphorylation of many
proteins not known to be directly involved in IL-2/15R signaling, indicating that the
signaling response to IL-2 and IL-15 is similar throughout the network.
F15R-Kit cells proliferate equivalently in response to continuous stimulation with IL-2 and
IL-15 but differ in their response to pulse stimulation
To understand how virtually identical signaling networks could give rise to qualitatively
different phenotypic responses to IL-2 or IL-15 stimulation, we probed potentially revealing
quantitative characteristics of receptor signaling and resultant cell phenotypic responses. To
identify differential proliferation responses to the two cytokines, we counted viable F15R-
Kit cell numbers following continuous stimulation with IL-2 or IL-15 over five days. F15R-
Kit cells cultured in the continuous presence of IL-2 or IL-15 proliferated equivalently
(figure 3A). To account for the effects of cytokine α-chain binding affinity on cell
proliferation, F15R-Kit cells were cultured with an IL-2 mutant (mtIL-2) engineered to have
a binding affinity for IL-2Rα approaching that of the IL-15-IL-15Rα complex. Proliferation
of F15R-Kit cells cultured with mtIL-2 was quantitatively equivalent to cells cultured with
either IL-2 or IL-15 (figure 3A). To compare the proliferative response of F15R-Kit cells
pulse stimulated with IL-2, IL-15, or mtIL-2 for a defined 30 minutes, we used the pulse
bioassay protocol described previously.20 Consistent with previous observations, F15R-Kit
cells pulsed with IL-15 or mtIL-2 proliferated over a period of days without additional
cytokine stimulation, while wild type IL-2 pulsed cells did not proliferate (figure 3B).
Increased initial receptor occupancy and surface persistence of cytokines after pulse
stimulation mediates proliferation through increased duration of IL-2/15R signaling after
cytokine withdrawal
The proliferative response of F15R-Kit cells to cytokine pulse stimulation was previously
found to be directly correlated to the initial cytokine surface receptor occupancy and surface
persistence.20 We hypothesized that increased initial receptor occupancy and surface
persistence may regulate proliferation through increased duration of IL-2/15R signal
transduction after cytokine withdrawal. To test this hypothesis, the surface cytokine levels,
IL-2/15R signal strength, and proliferation of F15R-Kit cells pulsed with IL-2, IL-15, or
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mtIL-2 were measured simultaneously at multiple time-points after cytokine withdrawal. As
STAT5 proteins are tyrosine phosphorylated directly through association with the IL-2Rβ
receptor, intracellular levels of phosphorylated STAT5 (pSTAT5) represent a proxy for
IL-2/15R signal strength.10 F15R-Kit cells pulsed with IL-15 or mtIL-2 showed higher
levels of surface-bound cytokine and surface persistence after cytokine withdrawal
compared to wild-type IL-2 (figures 4A & 4B). Pulse stimulation of F15R-Kit cells with
IL-2, IL-15, or mtIL-2 initially resulted in a quantitatively equivalent increase in pSTAT5
levels (figure 4A). Cells pulsed with IL-15 or mtIL-2 maintained high pSTAT5 levels for up
to 72h after cytokine withdrawal, whereas the pSTAT5 levels of cells pulsed with wild-type
IL-2 returned to basal levels by 6h (figure 4C, supplementary figure S2A–B).
F15R-Kit cell proliferation requires a continuous signal input from the IL-2/15 receptor
F15R-kit cells pulsed with wild-type IL-2 maintained high pSTAT5 levels for up to 6–8h
after cytokine withdrawal, yet did not proliferate. We hypothesized that a minimum duration
of IL-2/15 receptor signaling might be required for T cell proliferation. To test this
hypothesis, CFSE labeled F15R-Kit cells were cultured with a saturating IL-2 dose, and a
saturating dose of Jak Inhibitor I (JI) was added at multiple time-points after cytokine
addition. Saturating doses were defined as the cytokine dose that induced maximal STAT5
phosphorylation and the JI dose that resulted in maximum reduction in pSTAT5 levels after
cytokine stimulation. The addition of JI at specified time-points after cytokine stimulation
allowed experimental control over the duration of IL-2/15R signaling experienced by the
F15R-Kit cells. The addition of JI at any time-point up to 30h after IL-2 addition prevented
F15R-Kit cells from undergoing cell division (figure 4D). These results suggest that
continuous signal transduction from the IL-2/15R is required for T cell proliferation.
F15R-Kit cell proliferation, cell size, and glycolytic activity respond distinctly to IL-2/15R
signal strength
To investigate the role of IL-2/15R signal strength in the regulation of T cell proliferation
and cell size, CFSE labeled F15R-Kit cells were cultured with increasing doses of IL-2 or
IL-15; for each condition, cell proliferation and cell size were measured over multiple days.
F15R-Kit cell size increased with increasing cytokine dose (figure 5A & 5C) but
proliferation remained equivalent for IL-2 or IL-15 stimulated cells (figure 5B & 5C). As the
relationship between cytokine dose, cell size, and cell proliferation was identical for both
IL-2 and IL-15, we hypothesized that T cell size and proliferation were regulated directly
through the IL-2/15 receptor signal strength in a cytokine independent manner. To test this
hypothesis, CFSE labeled F15R-Kit cells were cultured with a saturating dose of IL-2 or
IL-15 along with a range of JI doses, allowing for direct control of the IL-2/15R signal
strength upon IL-2 or IL-15 stimulation (figure 6A). For either IL-2 or IL-15 stimulation,
F15R-Kit cell size decreased with increasing JI concentration (figure 6B), while
proliferation remained unaffected (figure 6C). The relative differences in F15R-Kit cell size
and the equivalent relative F15R-Kit proliferation levels were maintained for up to 6 days in
culture (figure 6B–C).
Increase in T cell size due to antigen or cytokine stimulation is related to increased cellular
metabolic activity.31–34 To determine whether an increase in F15R-Kit cell size with
IL-2/15R signal strength was also correlated with an increase in cell metabolism, we
measured glucose consumption and lactate production by F15R-Kit cells maintained in
culture with IL-2 or IL-15 in the presence of varying doses of JI. Glucose consumption and
lactate production decreased with increasing JI dose for cells stimulated with either IL-2 or
IL-15 (figure 6D–E), suggesting that metabolic activity is dependent on signal strength from
the receptor, independent of cytokine identity.
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Regulation of F15R-Kit cell size and proliferation through the IL-2/15 receptor signal
strength is quantitatively distinct and cytokine independent
To directly establish the quantitative relationship between signal strength, cell size, and
proliferation, CFSE labeled F15R-Kit cells were cultured with IL-2 or IL-15 along with a
range of JI doses. FSC, CFSE dilution, and intracellular pSTAT5 levels were measured
through flow cytometry after 48h in culture. CFSE dilution levels initially decreased with
increasing pSTAT5 levels but plateaued independent of further increase in pSTAT5 levels
beyond 40% of maximal pSTAT5 levels triggered by cytokine stimulation, suggesting a
digital relationship between cell proliferation and IL-2/15R signal strength (figure 7A). In
contrast to CFSE dilution, F15R-Kit FSC values increased linearly with respect to pSTAT5
levels, suggesting an analog relationship between cell size and signal strength (figure 7B).
The PI3K/AKT/mTOR pathway has been shown to play a direct role in the regulation of T
cell size and metabolic activity, and serine phosphorylation of 40S ribosomal protein S6
(pS6) is a reliable indicator of this pathway’s activation.18,35,36 Plotting F15R-Kit cell FSC
values with respect to pS6 levels revealed an analog relationship between F15R-Kit cell size
and mTOR pathway activation (figure 8), similar to our results for pSTAT5.
To determine whether IL-2/15R signal strength measurements alone were sufficient for
predicting F15R-Kit cell size and proliferation in response to cytokine stimulation, CFSE
labeled F15R-Kit cells were cultured with IL-2 or IL-15 along with three different doses of
JI. The stimulation, processing, and analysis of the varying cytokine and JI treatments were
performed simultaneously to minimize variations introduced through the experimental
techniques. Consistent with earlier results, the FSC of F15R-Kit cell size increased linearly
with receptor signal strength (figure 7C & supplementary figure S2C) but proliferation
remained identical (supplementary figure S2C). Data in figure 7C demonstrate that IL-2/15R
signal strength was not only sufficient but a superior indicator of F15R-Kit cell size
compared to cytokine identity, cytokine dose, or JI concentration.
The quantitative relationship between cell size, proliferation, and IL-2/15R signal strength
is conserved in antigen-activated primary human T lymphocytes
To determine the physiological relevance of the quantitative relationship between IL-2/15R
signal strength, cell size, and proliferation discovered using F15R-Kit cells, we replicated
the experiments with primary human CD4+ and CD8+ T lymphocytes. Primary T cells were
activated in vitro using anti-CD3 and anti-CD28 stimulation, which led to an up-regulation
of all four IL-2/15 receptor chain surface levels (supplementary figure S1C). Similar to
F15R-Kit cells, IL-2 and IL-15 stimulated CD4+ and CD8+ T cells decreased in size with
increasing JI dose (figure 9A & 9C) while proliferation levels remained unaffected (figure
9B & 9D). Differences in cell size were maintained for multiple days in cell culture, during
which time the cell proliferation rates remained constant (figure 9A–D). Similar to F15R-Kit
cells, plotting FSC and CFSE dilution levels of the primary human T cells with respect to
intracellular pSTAT5 levels as a proxy for IL-2/15R signal strength revealed an analog
relationship with cell size and a digital relationship with cell proliferation for both CD4+ and
CD8+ T lymphocytes (figures 9E–H).
Discussion
IL-2 and IL-15 signal through the same receptors on the surface of T cells, yet play distinct
roles in the T cell immune response physiologically and at the cellular level. Results from
the present study provide new insights into mechanisms by which IL-2 and IL-15 trigger
distinct phenotypes in T cells.
Arneja et al. Page 9
J Immunol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
To generate an unbiased, global, and quantitative view of the signal transduction triggered
by IL-2 and IL-15 stimulation in T cells, we quantified changes in the phosphotyrosine
proteome triggered in F15R-Kit cells upon IL-2 and IL-15 stimulation.22–25 With the
exception of a quantitative difference in STAM2 and VPS18 phosphorylation, IL-2 and
IL-15 stimulation resulted in qualitatively and quantitatively identical signal transduction
through the IL-2/15R in F15R-Kit cells. These results suggest that phenotypic differences
induced by IL-2 and IL-15 in T cells are likely not a result of distinct signal transduction
from the shared IL-2/15R. Interestingly, both STAM2 and VPS18 proteins are known to be
involved in the regulation of cytokine and growth factor receptor endocytosis and
intracellular trafficking.27–30 The effects of potential differences in receptor intracellular
trafficking on cellular phenotypes remain to be characterized.
Results from our investigation into the distinct proliferative responses of T cells to pulsed
stimulation with IL-2 or IL-15 revealed a critical role of IL-2/15R signal duration in
regulating T cell proliferation. We found that the increased receptor occupancy and surface
persistence of IL-15 and mtIL-2, a result of their higher α-chain binding affinity, drove
proliferation through prolonged duration of signaling from the receptor after cytokine
withdrawal compared to cells pulsed with wild-type IL-2. A closer examination of the
inability of F15R-Kit cells pulse stimulated with wild-type IL-2 to proliferate despite
signaling for ~6h revealed that T cell proliferation required a constant signal input from the
IL-2/15R. This result may be related to the role of IL-2 signaling in T cell peripheral
tolerance, where a requirement for constant IL-2/15R signaling for cell division might
ensure proliferation of activated T cells only during the early immune response, when high
levels of IL-2 are produced and secreted by antigen activated T lymphocytes.3,4,15,37
Investigation into the distinct metabolic activity triggered by IL-2 and IL-15 in T cells
revealed the critical role played by IL-2/15R signal strength in the regulation of T cell
proliferation and metabolism. We found that F15R-Kit cell size increased with IL-2/15R
signal strength while proliferation remained identical for both IL-2 and IL-15 stimulated
cells. As the relative differences in cell size were maintained over several days while
proliferation rates remained constant, the cell size differences were not a result of
differential rates of cell cycle progression. This result suggests that cell proliferation and
size were both directly regulated through IL-2/15R signal strength, but in a quantitatively
distinct manner. F15R-Kit cell proliferation changed digitally with IL-2/15R signal strength,
whereas F15R-Kit cell size showed an analog linear dependence on IL-2/15R signal
strength.
The regulation of T cell size by IL-2/15R signal strength appears to be mediated through its
effects on T cell metabolic activity, as glycolytic activity of F15R-Kit cells correlated
directly with IL-2/15R signal strength and cell size. Proliferation remained identical for cells
with glycolytic activity above a minimum threshold, suggesting that cytokine stimulation
triggers metabolic activity in excess of proliferative demand. Although not directly
measured in this study, the increase in glycolytic activity of F15R-Kit cells upon IL-2 or
IL-15 stimulation is likely a result of increased expression and activity of glucose
transporters (GLUTs) and metabolic enzymes.31–35,38 The analog relationship between
glycolytic activity and consequently cell size may be a result of the direct dependence of
GLUT and glycolytic enzyme expression levels on IL-2/15R signal strength.35,36,38,39 Our
results showing a linear relationship between cell size and mTOR pathway activation for
both IL-2 and IL-15 stimulated F15R-Kit cells lend support to this idea.36,38,39
Our experiments with primary human CD8+ and CD4+ T cells showed that the
quantitatively distinct and cytokine independent regulation of T cell size and proliferation is
a physiologically conserved mechanism for IL-2 and IL-15 mediated regulation of distinct T
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cell phenotypes. To our knowledge, this is the first time a stable analog relationship between
IL-2/15R signal strength and cell size has been demonstrated for primary human CD8+ and
CD4+ T lymphocytes. Interestingly, the significant difference in cell size upon IL-2 or IL-15
stimulation previously reported in mouse CD8+ T cells was not observed for either CD8+ or
CD4+ human T lymphocytes.18 It is possible that activated human T cells express a higher
amount of IL-15Rα on their surface compared to activated murine T cells either due to
inherent species specific differences or distinct stimulation protocols used (anti-CD3/CD28
for humans vs. antigenic peptides for mice). The higher IL-15Rα expression of human T
cells would result in similar IL-2/15R signal strength and consequently cell size for cells
stimulated with IL-2 and IL-15.
Recent studies in mouse models have revealed that IL-2 and IL-15 can differ in their mode
of presentation in vivo. Even though both IL-2 and IL-15 stimulate T cells as soluble
ligands,4,9 IL-15 is thought to be mainly presented through a process known as trans-
presentation.4,8,19,21 This mode of presentation involves the interaction of IL-15-IL-15Rα
complexes expressed on the surface of dendritic cells and macrophages with the IL-2/15βγc
complexes expressed on T cells.4,8,19,21 Although trans-presentation was not present in our
system, results from the current study can provide insights into its effects on IL-15
signaling. As IL-15-IL-15Rα complexes presented in trans can directly stimulate the
IL-2Rβγc complexes independent of the T cell surface expression of IL-15Rα, and no
known evidence exists of their ability to be internalized by the stimulated cells, trans
presentation can potentially increase the strength and duration of IL-15 signal transduction
relative to stimulation by soluble IL-15. 4,18,19,40 Our current results suggest that T cells
stimulated with IL-15 in trans would be metabolically more active, larger in size, and more
proliferative compared to cells stimulated with soluble IL-15. In support of this idea,
stimulation of T cells with soluble complexes of IL-15-IL-15Rα results in stronger and more
persistent signaling and a more potent phenotypic response compared to stimulation with
soluble IL-15.40,41 It is possible that soluble and trans-presented IL-15 play distinct roles
physiologically. Soluble IL-15 may primarily function to provide viability and proliferation
signals for T cell populations that express IL-15Rα chains on their surfaces, for instance in
the context of processes such as maintenance and self-renewal of memory T cells.
Alternatively, trans-presented IL-15 may primarily function to provide a spatially localized
“growth factor” like signal stimulating both metabolic activity and proliferation of T cells
independent of IL-15Rα expression, which may be critical for the generation and
maintenance of tissue localized effector T cell populations.
In summary, the present study investigated mechanisms allowing IL-2 and IL-15 to mediate
distinct phenotypes in T cells despite signaling through the same receptors. We found that
the strength and duration of a signaling pathway can directly affect cellular phenotypes, and
regulation of distinct phenotypes may not require activation of qualitatively distinct
signaling pathways. These results may explain the ability of cytokines to regulate different
phenotypes in T cells while signaling through shared receptors. In support of this, a recent
study explained differences in IL-7-elicited viability and proliferation behavior among
various mouse strain naive CD8+ T cells in terms of analogous quantitative dependences of
IL-7 receptor signaling strength and duration.42 As T cell effector functions and
differentiation are intimately linked to their metabolic activity, the quantitative regulation of
T cell metabolism and proliferation described in the present study may provide important
design principles for improved cytokine mediated immunotherapies.3–5,18,32 Engineering
mutant versions of IL-2 or IL-15 with defined effects on IL-2/15R signal strength and/or
duration can allow for a more precise control over the nature of T cell immune response
required for the treatment of a particular disease. Thus, our results may provide important
insights into the design of cytokine based immunotherapies for cancer, autoimmune
disorders, and infectious diseases.
Arneja et al. Page 11
J Immunol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding for this research was provided in part by NIH U54CA11927 and R01 AI065824. This work was partially
supported by the Institute for Collaborative Biotechnologies through grant W911NF-09-0001 from the U.S. Army
Research Office. The content of the information does not necessarily reflect the position or the policy of the
Government, and no official endorsement should be inferred.
The authors would like to thank Amanda Del Rosario for critical reading of the manuscript, members of the White
lab for technical assistance and helpful discussions, Maria Foley and Talitha Forcier for technical assistance with
isolation and culture of human T lymphocytes, Glen Pardis and the flow cytometry core facility at the Koch
Institute for assistance in flow cytometry experiments, Annie Gai (Wittrup Lab, MIT) for kindly providing F15R-
Kit cells and human IL-2 mutants, and Matthew Vander Heiden for helpful discussions.
Abbreviations
LC-MS/MS liquid chromatography tandem mass spectrometry
pTyr phosphotyrosine
FSC forward scatter
SSC side scatter
JI Jak Inhibitor I
References
1. Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E,
Waldmann TA. A lymphokine, provisionally designated interleukin T and produced by a human
adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated
killer cells. Proc Natl Acad Sci U S A. 1994; 91:4935–4939. [PubMed: 8197160]
2. Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science. 1984;
224:1312–1316. [PubMed: 6427923]
3. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for
cancer. Cytokine Growth Factor Rev. 2002; 13:169–183. [PubMed: 11900992]
4. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and
vaccine design. Nat Rev Immunol. 2006; 6:595–601. [PubMed: 16868550]
5. Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD,
Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris
JC. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with
T-cell large granular lymphocytic leukemia. Blood. 2013; 121:476–484. [PubMed: 23212516]
6. de Jong JL, Farner NL, Widmer MB, Giri JG, Sondel PM. Interaction of IL-15 with the shared IL-2
receptor beta and gamma c subunits. The IL-15/beta/gamma c receptor-ligand complex is less stable
than the IL-2/beta/gamma c receptor-ligand complex. J Immunol. 1996; 156:1339–1348. [PubMed:
8568232]
7. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman
D, Anderson D. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine
IL-15. Embo j. 1994; 13:2822–2830. [PubMed: 8026467]
8. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR, Pande VS, Li P, Moraga I, Spolski R,
Ozkan E, Leonard WJ, Garcia KC. Mechanistic and structural insight into the functional dichotomy
between IL-2 and IL-15. Nat Immunol. 2012; 13:1187–1195. [PubMed: 23104097]
9. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling
complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006;
103:2788–2793. [PubMed: 16477002]
Arneja et al. Page 12
J Immunol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
10. Gaffen SL. Signaling domains of the interleukin 2 receptor. Cytokine. 2001; 14:63–77. [PubMed:
11356007]
11. Delespine-Carmagnat M, Bouvier G, Bertoglio J. Association of STAT1, STAT3 and STAT5
proteins with the IL-2 receptor involves different subdomains of the IL-2 receptor β chain.
European Journal of Immunology. 2000; 30:59–68. [PubMed: 10602027]
12. Kovanen PE, Rosenwald A, Fu J, Hurt EM, Lam LT, Giltnane JM, Wright G, Staudt LM, Leonard
WJ. Analysis of gamma c-family cytokine target genes. Identification of dual-specificity
phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2
signaling. J Biol Chem. 2003; 278:5205–5213. [PubMed: 12435740]
13. Kovanen PE, Young L, Al-Shami A, Rovella V, Pise-Masison CA, Radonovich MF, Powell J, Fu
J, Brady JN, Munson PJ, Leonard WJ. Global analysis of IL-2 target genes: identification of
chromosomal clusters of expressed genes. Int Immunol. 2005; 17:1009–1021. [PubMed:
15980098]
14. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol.
2004; 4:665–674. [PubMed: 15343366]
15. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor α chain
regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995; 3:521–
530. [PubMed: 7584142]
16. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A. IL-15 receptor
maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity.
1998; 9:669–676. [PubMed: 9846488]
17. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis.
Annu Rev Immunol. 2006; 24:657–679. [PubMed: 16551262]
18. Cornish GH, Sinclair LV, Cantrell DA. Differential regulation of T-cell growth by IL-2 and IL-15.
Blood. 2006; 108:600–608. [PubMed: 16569767]
19. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans
to neighboring cells. Immunity. 2002; 17:537–547. [PubMed: 12433361]
20. Rao BM, Driver I, Lauffenburger DA, Wittrup KD. High-affinity CD25-binding IL-2 mutants
potently stimulate persistent T cell growth. Biochemistry. 2005; 44:10696–10701. [PubMed:
16060678]
21. Burkett PR, Koka R, Chien M, Chai S, Chan F, Ma A, Boone DL. IL-15R alpha expression on
CD8+ T cells is dispensable for T cell memory. Proc Natl Acad Sci U S A. 2003; 100:4724–4729.
[PubMed: 12671073]
22. Ficarro SB, McCleland ML, Stukenberg PT, Burke DJ, Ross MM, Shabanowitz J, Hunt DF, White
FM. Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces
cerevisiae. Nat Biotechnol. 2002; 20:301–305. [PubMed: 11875433]
23. Johnson H, Del Rosario AM, Bryson BD, Schroeder MA, Sarkaria JN, White FM. Molecular
characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor
xenografts. Mol Cell Proteomics. 2012; 11:1724–1740. [PubMed: 22964225]
24. Kim JE, White FM. Quantitative analysis of phosphotyrosine signaling networks triggered by CD3
and CD28 costimulation in Jurkat cells. J Immunol. 2006; 176:2833–2843. [PubMed: 16493040]
25. Iwai LK, Benoist C, Mathis D, White FM. Quantitative phosphoproteomic analysis of T cell
receptor signaling in diabetes prone and resistant mice. J Proteome Res. 2010; 9:3135–3145.
[PubMed: 20438120]
26. Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S, Kita K, Uchino H.
Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic
lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood.
1987; 70:1069–1072. [PubMed: 3115332]
27. Endo K, Takeshita T, Kasai H, Sasaki Y, Tanaka N, Asao H, Kikuchi K, Yamada M, Chenb M,
O’Shea JJ, Sugamura K. STAM2, a new member of the STAM family, binding to the Janus
kinases. FEBS Lett. 2000; 477:55–61. [PubMed: 10899310]
28. Stuible M, Abella JV, Feldhammer M, Nossov M, Sangwan V, Blagoev B, Park M, Tremblay ML.
PTP1B targets the endosomal sorting machinery: dephosphorylation of regulatory sites on the
Arneja et al. Page 13
J Immunol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
endosomal sorting complex required for transport component STAM2. J Biol Chem. 2010;
285:23899–23907. [PubMed: 20504764]
29. Huizing M, Didier A, Walenta J, Anikster Y, Gahl WA, Kramer H. Molecular cloning and
characterization of human VPS18, VPS 11, VPS16, and VPS33. Gene. 2001; 264:241–247.
[PubMed: 11250079]
30. Peng C, Ye J, Yan S, Kong S, Shen Y, Li C, Li Q, Zheng Y, Deng K, Xu T, Tao W. Ablation of
vacuole protein sorting 18 (Vps18) gene leads to neurodegeneration and impaired neuronal
migration by disrupting multiple vesicle transport pathways to lysosomes. J Biol Chem. 2012;
287:32861–32873. [PubMed: 22854957]
31. Bauer DE, Harris MH, Plas DR, Lum JJ, Hammerman PS, Rathmell JC, Riley JL, Thompson CB.
Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand.
Faseb j. 2004; 18:1303–1305. [PubMed: 15180958]
32. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell
response. Nat Rev Immunol. 2005; 5:844–852. [PubMed: 16239903]
33. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell
proliferation. Annu Rev Cell Dev Biol. 2011; 27:441–464. [PubMed: 21985671]
34. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. Growth factors
can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol.
2001; 21:5899–5912. [PubMed: 11486029]
35. Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC. IL-7 promotes Glut1 trafficking and
glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood. 2008;
111:2101–2111. [PubMed: 18042802]
36. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation,
function, and metabolism. Immunity. 2010; 33:301–311. [PubMed: 20870173]
37. Long M, Adler AJ. Cutting edge: Paracrine, but not autocrine, IL-2 signaling is sustained during
early antiviral CD4 T cell response. J Immunol. 2006; 177:4257–4261. [PubMed: 16982857]
38. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via
phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell.
2007; 18:1437–1446. [PubMed: 17301289]
39. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory
CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin.
Immunity. 2010; 32:67–78. [PubMed: 20060330]
40. Sato N, Patel HJ, Waldmann TA, Tagaya Y. The IL-15/IL-15Ralpha on cell surfaces enables
sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl
Acad Sci U S A. 2007; 104:588–593. [PubMed: 17202253]
41. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J. Converting IL-15 to
a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006; 103:9166–
9171. [PubMed: 16757567]
42. Palmer MJ V, Mahajan S, Chen J, Irvine DJ, Lauffenburger DA. Signaling thresholds govern
heterogeneity in IL-7-receptor-mediated responses of naive CD8(+) T cells. Immunol Cell Biol.
2011; 89:581–594. [PubMed: 21339767]
43. Damjanovich S, Bene L, Matko J, Alileche A, Goldman CK, Sharrow S, Waldmann TA.
Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T. Proc Natl Acad Sci
U S A. 1997; 94:13134–13139. [PubMed: 9371812]
44. de Bakker BI, Bodnár A, van Dijk EM, Vámosi G, Damjanovich S, Waldmann TA, van Hulst NF,
Jenei A, Garcia-Parajo MF. Nanometer-scale organization of the alpha subunits of the receptors
for IL2 and IL15 in human T lymphoma cells. J Cell Sci. 2008; 121:627–633. [PubMed:
18287585]
45. Vamosi G, Bodnar A, Vereb G, Jenei A, Goldman CK, Langowski J, Toth K, Matyus L, Szollosi J,
Waldmann TA, Damjanovich S. IL-2 and IL-15 receptor alpha-subunits are coexpressed in a
supramolecular. Proc Natl Acad Sci U S A. 2004; 101:11082–11087. [PubMed: 15263076]
46. Liparoto SF, Myszka DG, Wu Z, Goldstein B, Laue TM, Ciardelli TL. Analysis of the role of the
interleukin-2 receptor gamma chain in ligand binding. Biochemistry. 2002; 41:2543–2551.
[PubMed: 11851401]
Arneja et al. Page 14
J Immunol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
47. Pesesse X, Dewaste V, De Smedt F, Laffargue M, Giuriato S, Moreau C, Payrastre B, Erneux C.
The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal
growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in
EGF-stimulated COS-7 cells. J Biol Chem. 2001; 276:28348–28355. [PubMed: 11349134]
48. Prasad N, Topping RS, Decker SJ. Src family tyrosine kinases regulate adhesion-dependent
tyrosine phosphorylation of 5′-inositol phosphatase SHIP2 during cell attachment and spreading
on collagen I. J Cell Sci. 2002; 115:3807–3815. [PubMed: 12235291]
49. Kurzer JH, Argetsinger LS, Zhou YJ, Kouadio JL, O’Shea JJ, Carter-Su C. Tyrosine 813 is a site
of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol Cell Biol. 2004;
24:4557–4570. [PubMed: 15121872]
50. Benitah SA, Valerón PF, Rui H, Lacal JC. STAT5a activation mediates the epithelial to
mesenchymal transition induced by oncogenic RhoA. Mol Biol Cell. 2003; 14:40–53. [PubMed:
12529425]
51. Rodriguez R, Matsuda M, Storey A, Katan M. Requirements for distinct steps of phospholipase
Cgamma2 regulation, membrane-raft-dependent targeting and subsequent enzyme activation in B-
cell signalling. Biochem J. 2003; 374:269–280. [PubMed: 12780340]
52. Fu G, Chen Y, Schuman J, Wang D, Wen R. Phospholipase Cgamma2 plays a role in TCR signal
transduction and T cell selection. J Immunol. 2012; 189:2326–2332. [PubMed: 22837484]
53. Cheng H, Ross JA, Frost JA, Kirken RA. Phosphorylation of human Jak3 at tyrosines 904 and 939
positively regulates its. Mol Cell Biol. 2008; 28:2271–2282. [PubMed: 18250158]
54. Kim MJ, Kim E, Ryu SH, Suh PG. The mechanism of phospholipase C- gamma1 regulation. Exp
Mol Med. 2000; 32:101–109. [PubMed: 11048639]
55. Brunati AM, Donella-Deana A, James P, Quadroni M, Contri A, Marin O, Pinna LA. Molecular
features underlying the sequential phosphorylation of HS1 protein and its association with c-Fgr
protein-tyrosine kinase. J Biol Chem. 1999; 274:7557–7564. [PubMed: 10066823]
56. Cavnar PJ, Mogen K, Berthier E, Beebe DJ, Huttenlocher A. The actin regulatory protein HS1
interacts with Arp2/3 and mediates efficient neutrophil chemotaxis. J Biol Chem. 2012;
287:25466–25477. [PubMed: 22679023]
57. Gotoh N, Toyoda M, Shibuya M. Tyrosine phosphorylation sites at amino acids 239 and 240 of
Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/
mitogen-activated protein kinase activation. Mol Cell Biol. 1997; 17:1824–1831. [PubMed:
9121430]
58. Nakahira M, Tanaka T, Robson BE, Mizgerd JP, Grusby MJ. Regulation of signal transducer and
activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity. 2007; 26:163–
176. [PubMed: 17306571]
59. Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;
66:105–143. [PubMed: 22569528]
60. Lennartsson J, Burovic F, Witek B, Jurek A, Heldin CH. Erk 5 is necessary for sustained PDGF-
induced Akt phosphorylation and inhibition of apoptosis. Cell Signal. 2010; 22:955–960.
[PubMed: 20138986]
61. Yang X, Dutta U, Shaw LM. SHP2 mediates the localized activation of Fyn downstream of the
α6β4 integrin to promote carcinoma invasion. Mol Cell Biol. 2010; 30:5306–5317. [PubMed:
20855525]
62. Lu W, Gong D, Bar-Sagi D, Cole PA. Site-specific incorporation of a phosphotyrosine mimetic
reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell. 2001; 8:759–769.
[PubMed: 11684012]
Arneja et al. Page 15
J Immunol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Mass spectrometry based phosphotyrosine profiling of F15R-Kit cells stimulated with
IL-2 and IL-15
(A) Schematic diagram of mass spectrometry based quantitative phosphotyrosine profiling
experimental workflow. (B) Heat maps depicting 85 phosphorylation sites on 81 proteins
quantified across F15R-Kit cell stimulated with IL-2 or IL-15 for 15 min. Heat maps
represent log 2 transformed iTRAQ-8plex fold change values relative to one replicate of
unstimulated F15R-Kit cells. The fold changes depicted for IL-2 and IL-15 are an average of
3 technical replicates. (C) Cellular processes regulated by the 41 proteins with greater than
1.5 fold increase in phosphorylation level upon IL-2 and IL-15 stimulation. (D) The relative
increase in phosphorylation levels of canonical IL-2/15R signaling proteins triggered by
IL-2 and IL-15 in F15R-Kit cells.
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Figure 2. Quantification of phosphotyrosine sites regulated by IL-2 and IL-15 stimulation of
F15R-Kit cells
(A) Quantification of phosphotyrosine sites differentially regulated by IL-2 and IL-15
stimulation. iTRAQ fold changes in F15R-Kit cells stimulated with IL-2 and IL-15
normalized to unstimulated cells. Data represent an average of 3 biological replicates. * p-
value <0.05. (B) Quantification of phosphotyrosine sites on canonical signaling proteins of
the IL-2/15R signaling pathways. iTRAQ fold changes in F15R-Kit cells stimulated with
IL-2 and IL-15 normalized to unstimulated cells. Data represent an average of 3 biological
replicates.
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Figure 3. F15R-Kit cells proliferate equivalently in response to a continuous, but not pulsed,
stimulation by IL-2, IL-15, and mtIL-2
(A) Viable cell numbers over time for F15R-Kit cells cultured in the continuous presence of
500pM IL-2, IL-15, mtIL-2, or culture medium alone. (B) Viable cell numbers over time of
F15R-Kit cells pulsed for 30min with 500pM IL-2, IL-15, and mtIL-2. Viable cell numbers
were determined using Trypan Blue exclusion. Data represent Mean ± Standard Deviation
(SD) for three independent experiments.
Arneja et al. Page 18
J Immunol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. F15R-Kit cell proliferation requires continuous activation of the IL-2/15R signaling
(A) Representative flow cytometry histograms showing surface cytokine and intracellular
pSTAT5 levels in F15R-Kit cells stimulated with 500pM of the indicated cytokine for
30min (solid histograms). Dotted histograms represent unstimulated cells. (B) Surface-
bound cytokine levels and (C) intracellular pSTAT5 levels of F15R-Kit cells, pulse
stimulated with 500pM cytokine measured at the indicated time points after cytokine
withdrawal. Data represent median fluorescence intensity (MFI) of surface cytokine and
pSTAT5 levels normalized to MFI of cells stimulated with IL-15 at the 30min time-point.
(D) CFSE dilution values (left panel) and representative histograms of F15R-Kit CFSE
levels (right panel) experiencing a defined duration of IL-2/15 receptor signaling, ***αFW <
0.001 compared to unstimulated cells. CFSE dilution values represent the ratio of CFSE
MFI levels of cells cultured with IL-2 and JI to CFSE MFI of unstimulated cells 48h after
cytokine addition. Solid histograms represent CFSE values for F15R-Kit cells cultured with
IL-2 and JI and dashed histograms represent CFSE values of unstimulated cells 48h after
cytokine addition. Data represent average ± SD for 3 independent experiments.
Arneja et al. Page 19
J Immunol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. F15R-Kit cell size increases with cytokine dose but proliferation remains identical
(A) Median FSC values for F15R-Kit cells cultured for 48h with the indicated doses of IL-2
or IL-15 normalized to the 100pM dose for each cytokine. *αfw < 0.05, **αfw < 0.01,
***αfw < 0.001. (B) Plot showing the ratios of the CFSE values of F15R-Kit cells cultured
with the indicated dose of cytokine to the unstimulated cells at 48h. ***αfw < 0.001
compared to unstimulated cells. (C) Representative flow cytometry dot plots showing
forward scatter and histograms showing CFSE levels of F15R-Kit cells 48h after treatment
with the indicated dose of IL-2 or IL-15. Dotted histograms represent unstimulated cells.
Data represent Mean ± SD for 3 independent replicates.
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Figure 6. F15R-Kit cell size and glycolytic activity increases with increasing IL-2/15 receptor
signal strength while proliferation remains identical
Cytokine starved F15R-Kit cells were pretreated with the indicated dose of JAK Inhibitor I,
stimulated with a 500pM dose of cytokine, and intracellular pSTAT5 levels, forward scatter,
and CFSE levels measured at the indicated time-points using flow cytometry. (A) F15R-Kit
intracellular pSTAT5 levels 15min after addition of IL-2 or IL-15. (B) F15R-Kit cells
forward scatter values at the indicated time-periods after the addition of IL-2 or IL-15. (C)
CFSE dilution levels compared to the unstimulated control at the indicated time points for
cells cultured with IL-2 or IL-15. Glucose consumption and lactate production by F15R-Kit
cells treated with the indicated dose of JAK Inhibitor I and stimulated with 500pM of (D)
IL-2 or (E) IL-15, *αFW < 0.05, **αFW < 0.01 compared to 0nM JI condition. Data
represent Mean ± SD for 3 independent replicates.
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Figure 7. Quantitatively distinct regulation of F15R-Kit cell size and proliferation through the
IL-2/15 receptor signal strength
CFSE dilution and FSC levels plotted against intracellular pSTAT5 levels of F15R-Kit cells
cultured for 48h with multiple doses of JAK Inhibitor I and 500pM IL-2 (black diamonds) or
500pM IL-15 (gray circles) (A–B). (A) CFSE dilution vs. pSTAT5 levels. The black dotted
lines represent the threshold signal strength above which proliferation is identical and
independent of the specific pSTAT5 level. CFSE dilution values between 0.6 and 1
represent median fluorescence for populations where > 0% but <100% of cells complete one
cell division. (B) Forward scatter vs. pSTAT5 levels for cells with signal strength above the
threshold indicated in figure 5A. (C) Forward scatter vs. pSTAT5 levels of F15R-Kit cells
cultured with the indicated doses of JAK Inhibitor I and 500pM IL-2 (black diamonds) or
500pM IL-15 (gray circles). IL-2/15 receptor signal strength is a superior predictor of cell
size compared to JAK Inhibitor I dose, cytokine dose, or cytokine identity.
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Figure 8. F15R-Kit cell size vs. mTOR signaling
Forward scatter vs. 40S ribosomal protein S6 (pS6) levels of F15R-Kit cells cultured with
various doses of JI. Forward scatter and pS6 values measured 96h after cytokine addition for
cells stimulated with (A) 500pM IL-2 (black diamonds) or (B) 500pM IL-15 (gray circles).
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Figure 9. Quantitatively distinct regulation of cell size and proliferation through the IL-2/15
receptor signal strength in primary human T lymphocytes
Primary human CD4+ and CD8+ T cells were activated with anti-CD3 and anti-CD28
stimulation, treated with the indicated JAK Inhibitor I dose, and stimulated with 1nM IL-2
or IL-15. Forward scatter of (A) CD4+ T cells and (C) CD8+ T cells at the indicated time-
points after cytokine addition. CFSE dilution values for (B) CD4+ T cells and (D) CD8+ T
cells at the indicated time-points after cytokine addition. Non-activated T cells were used as
the negative control for measuring CFSE dilution. Forward scatter vs. intracellular pSTAT5
levels at 48h after cytokine addition for (E) CD4+ T cells (gray circles) and (F) CD8+ T cells
(black squares). CFSE dilution vs. intracellular pSTAT5 levels at 48h after cytokine addition
for (G) CD4+ T (gray circles) cells and (H) CD8+ T (black squares) cells.
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